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Abstract
Background:  A possible method of finding physiological markers of multiple sclerosis (MS) is the
application of EEG quantification (QEEG) of brain activity when the subject is stressed by the demands of
a cognitive task. In particular, modulations of the spectral content that take place in the EEG of patients
with multiple sclerosis remitting-relapsing (RRMS) and benign multiple sclerosis (BMS) during a visuo-
spatial task need to be observed.
Methods: The sample consisted of 19 patients with RRMS, 10 with BMS, and 21 control subjects. All
patients were free of medication and had not relapsed within the last month. The power spectral density
(PSD) of different EEG bands was calculated by Fast-Fourier-Transformation (FFT), those analysed being
delta, theta, alpha, beta and gamma. Z-transformation was performed to observe individual profiles in each
experimental group for spectral modulations. Lastly, correlation analyses was performed between QEEG
values and other variables from participants in the study (age, EDSS, years of evolution and cognitive
performance).
Results: Nearly half (42%) the RRMS patients showed a statistically significant increase of two or more
standard deviations (SD) compared to the control mean value for the beta-2 and gamma bands (F = 2.074,
p = 0.004). These alterations were localized to the anterior regions of the right hemisphere, and bilaterally
to the posterior areas of the scalp. None of the BMS patients or control subjects had values outside the
range of ± 2 SD. There were no significant correlations between these values and the other variables
analysed (age, EDSS, years of evolution or behavioural performance).
Conclusion: During the attentional processing, changes in the high EEG spectrum (beta-2 and gamma) in
MS patients exhibit physiological alterations that are not normally detected by spontaneous EEG analysis.
The different spectral pattern between pathological and controls groups could represent specific changes
for the RRMS patients, indicative of compensatory mechanisms or cortical excitatory states representative
of some phases during the RRMS course that are not present in the BMS group.
Published: 24 November 2008
BMC Neurology 2008, 8:44 doi:10.1186/1471-2377-8-44
Received: 16 April 2008
Accepted: 24 November 2008
This article is available from: http://www.biomedcentral.com/1471-2377/8/44
© 2008 Vazquez-Marrufo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
Page 2 of 12
(page number not for citation purposes)
Background
Multiple sclerosis (MS) is generally regarded as a chronic
inflammatory demyelinating condition leading to focal
demyelination plaques in white matter, although recent
studies have demonstrated the presence of lesions in the
cerebral cortex and brain stem nuclei [1,2]. Axons can be
damaged either within inflammatory lesions [3] or, at a
later stage, in chronically demyelinated plaques due to the
lack of trophic support [4].
Along with the pathophysiology, it has been estimated
that cognitive impairment in MS occurs in 40–70% of
cases, probably resulting from disruption of cortical and
subcortical pathways as a consequence of demyelation
and axonal transection [5,6]. Nevertheless, great variabil-
ity exists in cognitive performance of individual MS
patients, implying that cognitive preservation and deteri-
oration occurs during the evolution of the disease [7,8].
Different forms of MS vary widely in their typical clinical
course [9-11]. In most patients with MS, clinical onset is
characterized by relapses and remissions, with episodes of
neurological impairment. This typical clinical presenta-
tion in relapsing-remitting multiple sclerosis (RRMS)
accounts for >80% of cases. Most of these patients inevita-
bly progress towards disability (secondary progressive
multiple sclerosis, SPMS). Another group of patients do
not have relapses at the onset of MS, but steadily accumu-
late disability over time (primary progressive multiple
sclerosis, PPMS) [12,13].
MS is characterized by a great heterogeneity in its long-
term prognosis and the distinctions between these typical
clinical phenotypes are not absolute. Taking SPMS as an
example, the time to conversion, the rate of progression
and the relative contribution of relapses and progression
may vary dramatically. In some patients, a 'benign' clini-
cal course (BMS) is also observed. Although the definition
is arbitrary, the prevalence of BMS relates to 10–20% of
patients whose EDSS score remains below 3 or 3.5 (mild
disability) after at least 10 or 15 years from the disease
onset [14-17].
One of the challenges of MS is to distinguish different
physiological alterations among the diverse clinical sub-
types [18]. In particular, it is desirable to find alterations
that start from the early beginning of the disease, which
would allow a fast and accurate diagnostic classification of
the patient and an easier decision about its management
[19].
The most relevant paraclinical technique used in the early
evaluation of MS is probably MRI [20]. However, MRI
gives a little specificity in differentiating between MS
groups, although new approaches (fMRI or Diffusion Ten-
sor Imaging, DTI) seem promising for future investiga-
tions [21-23].
Due to the fact that MS is a demyelination disease, the lack
of myelin alters the physiological activity of neurons in
the central nervous system (CNS). One means of analys-
ing this alteration is the electroencephalogram (EEG) that
records mainly the neural activity of cortical neurons. Sev-
eral studies have shown abnormal brain activity related to
neurological or psychiatric diseases [24-26].
In the case of MS, different studies have looked at possible
relationships between EEG activity and different aspects
of the MS disease. One study [27] observed changes in the
beta activity in fronto-central areas of the scalp which
were directly correlated with the disability score (the
higher disability score, the higher beta activity). Another
study [28] determined whether EEG could detect a possi-
ble association between epilepsy and MS, but it failed to
provide a satisfactory estimate of presence of abnormal
brain activity in MS patients. In the case of alterations of
the quantitative spectral content of the EEG (QEEG) in
MS, a common result is the heterogeneity of modulations
displayed in these patients along all bands [28,29]. More-
over, the correlation between spectral scores and the
degree of cognitive impairment assessed by neuropsycho-
logical testing was low in most cases [27,30]. In the latter
study, the cognitive status of a group of elderly subjects
indexed by the Mini Mental State Examination (MMSE)
was not significantly correlated with QEEG scores. For MS,
another study [27] showed that QEEG did not give as
valid an estimation of neurological parameters as SNE
(standard neurological examination).
Therefore, the general impression of QEEG in MS is that it
is of little use as a technique, but might support diagnostic
reports provided by neurological and/or MRI exploration
[31,32]. However, some experts in the QEEG field believe
it is possible to correlate different patterns in EEG spectra
with particular pathological conditions [24].
A new approach is needed to reveal specific patterns in MS
disease. Usually, the quantification of the EEG spectrum is
based in the application of Fast Fourier Transformation
(FFT) in concrete intervals under a passive condition of
the subject. But an alternative is to apply the same proto-
col during intervals when the subject is performing a cog-
nitive task that stresses areas that may have been afflicted
by the disease. One such study [33] showed an increment
in the high bands of the EEG spectrum (beta and gamma)
during an auditory oddball task in RRMS patients. The
modulations were present in the frontal areas of the scalp
and might have represented a cognitive impairment
related to automatic reorientation mechanisms of the
auditory attentional system.BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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With evidence of specific patterns of QEEG in different
neuropathologies and the knowledge that abnormal brain
activity in MS patients can occur when a cognitive task
provokes a stress condition, the main question was posed
as to whether it would it be possible to distinguish differ-
ent physiological profiles in diverse groups of MS
patients? Of particularly interest would be to find specific
physiological markers that distinguish between the BMS
and RRMS groups because an early diagnosis of the type
of MS could greatly help in deciding therapy and future
management.
Hence, our principal aim is to report possible QEEG alter-
ations in RRMS and BMS patients during the execution of
an attentional task that involves many areas in the brain,
i.e. in all probability, those that are probably impaired by
their pathological condition. In particular, we have ana-
lysed the QEEG and behavioural performance elicited
during a visuo-spatial task (Posner paradigm), which con-
sists of trials with central cues indicating the most likely
position of a subsequent target that has to be discrimi-
nated by the subject. In some cases, the cue indicates cor-
rectly the future location of the target ("valid trials"),
whereas when the cue directs attention to the opposite
area where the target will be presented, these trials are
defined as "invalid". Typically, longer reaction times were
found for invalid trials compared to valid ones [34]. The
comparison between valid and invalid trials shows that it
is possible to study the fixation of our spatial attention in
the visual field and the cost related in shifting the spatial
attention to another area [34,35].
The specific objectives in the study were the following: 1)
to check if there are diverse patterns of spectral content for
different groups of patients compared to a normal group
matched in age, gender and educational status (in the
affirmative case, the present study seeks to test if these dif-
ferences are consistent through all subjects or are present
in some of them but not all): 2) to compare the results
obtained with a visual modality with those of a previous
study [33] using an auditory attentional paradigm (the
major concern are the bands that are altered and the
topography exhibited by them): and 3) to carry out a cor-
relation analysis between QEEG scores and several scores
(neurological and psychophysiological measures).
Methods
Subjects and procedure
Three different groups of subjects participated in the
study: The first group included 19 patients (women 14;
age 36.95 ± 7.71 years old) diagnosed with RRMS without
clear signs of motor impairment, and with disease dura-
tion of 5.42 ± 4.21 years. The score in Multiple Sclerosis
Expanded Disability Status Scale (EDSS) for this group
was always equal or fewer than 3.5 (mean: 1.58 ± 0.8).
The second group included 10 patients (women 7; age
40.50 ± 7.60 years old) diagnosed of BMS. These patients
suffered MS during 12.30 ± 4.22 years and at least 8 years
of disease evolution and scoring equal or fewer than 3.5
in the EDSS scale (mean: 2,00 ± 1.1). The data from both
clinical groups were compared with a group of 21 healthy
subjects (women 13; age 35.57 ± 7.82 years old) similar
in age, gender proportion and educational level. The
experimental protocol was approved by the ethical com-
mittee of the Hospital. After a full explanation about the
details of the experiment, a written consent statement was
obtained from MS patients and controls.
All patients participating in the study were classified using
the Poser criteria [9]. We include in the experiment only
subjects that were clinically stable at baseline (meaning
no exacerbations within several months before the partic-
ipation in the experiment, no medication at the time of
evaluation (at least one-month window and only a few
presented history of corticoids treatment in past relapses)
and no signs of depression. Patients were previously
assessed at the Multiple Sclerosis Unit of the Neurology
Service of the Virgen Macarena Hospital (Seville, Spain)
and participated voluntarily in the Psychophysiological
testing.
Experimental protocol
Behavioural responses were recorded during the Posner
paradigm. Five blocks with 200 trials each were presented.
There were pauses between blocks to prevent the appear-
ance of fatigue in the subjects. Each trial consisted in a
central cue (lasting 300 ms) pointing to the left or to the
right side of the screen, where a target (mandatory
response) or a standard stimulus (no response) appears.
Targets and standards also lasted 300 ms. The sequence of
cue and imperative stimulus lasted for 1.5 sec and the
inter-trial time was 1 sec. The cue (a white arrow)
appeared at the screen centre. In standard and target trials
the cue could point to the position where the stimulus
appears (valid trials, 80%) or to the opposite side (invalid
trials, 20%) (see Figure 1). The shape of the target stimuli
was a circle with a pattern of black and red checkerboard
subtending a visual angle of 2.46 degrees. The standards
presented the same shape as targets but the colours were
changed to black and white. Both stimuli appeared ran-
domly at left or right side in the visual field. Subjects had
to press the left button of the mouse with their dominant
hand when targets appeared in the left side, and the right
button when the target appeared on the right side. There-
fore, standard and target stimuli, depending on the cue
and the position in the visual field, could be left valid, left
invalid, right valid and right invalid. The paradigm used is
a modified version of Posner's paradigm [35] with a 75%
of standard stimuli.
The EEG was recorded from 13 electrodes (Fz, Cz, Pz, F3,
F4, C3, F4, P3, F4, T5, F6, O1, O2) from the 10–20 Inter-BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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national System [36]. The electrodes were referenced to
the left mastoid and re-referenced off-line to the right
mastoid. Data were filtered using a band-pass of 0.01–100
Hz (1/2 amplitude low- and high-frequency cut-offs); the
amplification gain was 20,000. The EOG was recorded
with bipolar recording by means of electrodes situated in
the external canthi of the ocular orbits and in the inferior
and superior positions of the left orbit. The impedance
was kept under 5 kΩ. Artefacts were automatically
detected and visually revised. The trials in which HEOG
artefacts higher than ± 70 μV were detected at electrodes
Fz, Cz or Pz, were rejected. The baseline was 100 ms prior
to the standard and target stimuli. The different experi-
mental conditions were averaged independently.
EEG analysis
The power spectral density for each band (PSD) was cal-
culated by means of the Fast-Fourier Transformation [37].
The selected time window for the analysis was from 512
ms previous to the onset of the imperative stimulus until
this onset (spectral resolution: 2 Hz). The digitisation rate
used for the EEG recording was of 500 Hz/channel that is
enough according to the Nyquist criteria to carry out an
appropriate analysis of all the frequencies of our study
[38]. The analysed bands were delta (0.5. 4 Hz), theta (5–
8 Hz), alpha (9–12 Hz), beta 1 (13–21 Hz) beta 2 (22–
30) gamma and (31–45 Hz). To avoid the leakage effect,
a cosine window was applied on the borders of the time
segment for analysis [38]. Logarithmic transformation
was also applied for any PSD value to achieve a valid nor-
mal distribution of these data and allow an ANOVA anal-
ysis [39].
The same analysis was performed for the background EEG
activity occurring during the pause blocks of the experi-
ment to test if the possible spectral modulations were
present even in the absence of the execution of the cogni-
tive task.
Normalization procedure
A normalization procedure was applied to the QEEG data
and behavioural measures to analyse the individual scores
of every subject from RRMS, BMS and control groups. The
purpose of this analysis is to observe whether heterogene-
ity or homogeneity is present in the abnormal PSD values
and behavioural measures along MS patients. To perform
this procedure the control group was taken as the norma-
tive sample (mean and standard deviation) and the Z-
Transformation was calculated following the formula:
Experimental Paradigm Figure 1
Experimental Paradigm. The onset of the imperative stimulus is on 0 milliseconds (ms). FFT: Fast Fourier Transformation 
Interval.BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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Z = (xi - X)/SD
Where xi is the PSD value for every patient in different
scalp derivations, X and SD were mean and standard devi-
ations calculated from the control group respectively. An
average of Z-values was calculated for each subject across
all scalp derivations that were different between RRMS
and the rest of the groups defined by the post-hoc analysis
performed for the PSD scores. In the present study these
derivations were F4, O1 and O2.
Statistical analysis
Behavioural analysis
The behavioural parameters analysed were reaction time
(RT) to the target stimuli and percentage of correct
responses (CR). An ANOVA design for repeated measure-
ments was used to analyse the RTs and CRs data. The
intra-subject factor was the validity of the cue (two levels:
valid vs. invalid) and the intersubject factor was the sub-
ject's group (three levels: RRMS, BMS and Control group).
QEEG analysis
An ANOVA design for repeated measures was used to ana-
lyse the spectral modulations. The intra-subject factors
were Spectral Band (delta, theta, alpha, beta-1, beta-2 and
gamma); Stimulus location (left and right); Hemisphere
(left and right); Electrode position (frontal, central, pari-
etal, occipital). Inter-subjects factor: Experimental group:
Control, RRMS and BMS). Greenhouse-Geisser correction
for sphericity was applied. Bonferroni correction was car-
ried out in multiple comparisons post-hoc analysis.
Correlation analysis
Correlations between subject data (age), clinical parame-
ters (EDSS or duration of disease), behavioural measures
(reaction time and percentage of correct responses) and
QEEG values were computed using Pearson's correlation
coefficient. Data was considered significant at the 0.05
level.
Results
Reaction time and percentage of correct responses
The first relevant result in the analysis of the behavioural
responses was the presence of the validity effect, i.e. of
faster responses for the valid condition compared to the
invalid ones (RRMS group (t = 4,319, p < 0.001) (18 ms)
and the control group (t = 9.773, p < 0.001) (33 ms)). In
the BMS group, the difference between the two conditions
was not statistically significant (12 ms) (see table 1).
Considering global responses, control subjects were faster
than both MS groups (F [2,47] = 8.891, p = 0.001) (CON:
457 ms ± 64; RRMS: 516 ms ± 56; BMS: 551 ms ± 67) (see
table 1). Moreover, ANOVA analysis revealed that an
interaction effect took place between these two factors "
cue × group" (F [2,47] = 8.990, p < 0.001). This result
links the differences between groups observed by the
main effect (the two MS groups have slower reaction times
than control group); and on the other hand, an effect of
validity exists in the RRMS and control groups that is not
found in the BMS group.
Regarding the percentage of correct responses, no differ-
ences were found among the valid and invalid conditions
of any of the groups. However, differences were observed
among the different experimental groups (F [2,47] =
4.627, p = 0.015). Post-hoc analysis showed that BMS
patients made significantly more errors than the control
and RRMS groups (p = 0.018) (CON: 96 ms ± 4; RRMS: 89
ms ± 15; BMS: 81 ms ± 22) (see table 1).
Quantitative EEG
In the spectral analysis, ANOVA analysis showed interac-
tions between the following variables "Spectral Band ×
Stimulus Location × Hemisphere × Electrode × Group"
Table 1: Descriptive and Statistical results of the behavioural data
Reaction Time Correct Responses %
Descriptive Valid Invalid Total Valid Invalid Total
BMS 545 ± 73 557 ± 65 551 ± 67 81 ± 24 80 ± 21 81 ± 22
RRMS 507 ± 57 525 ± 57 516 ± 56 89 ± 15 88 ± 15 89 ± 15
CON 441 ± 62 474 ± 66 457 ± 64 97 ± 3 96 ± 6 96 ± 4
Anova F p F P
Cue 43.007 <0.001 0.275 0.603
Group 8.891 0.001 4.627 0.015
Cue × Group 3.773 0.030 0.013 0.987
Post Hoc RRMS BMS CON RRMS BMS CON
RRMS 0.403 0.006 0.433 0.307
BMS <0.001 0.018
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group.BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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with a probability of (F [2,47] = 1.941, p = 0.009). Post-
hoc analysis indicated that the RRMS group was statisti-
cally significantly increased compared to the control
group for the high bands of the spectrum (beta-2 (22–30
Hz) and gamma (31–45 Hz), in both the occipital regions
(bilateral) (O1 and O2) and the frontal right hemisphere
region (F4) (see figure 2 and table 2). No differences were
found between the BMS and the control groups. The other
bands investigated showed no significant differences.
With respect to the background EEG, no differences in the
high spectral bands were detected between the groups
when subjects were not performing the attentional task.
Normalization
The results of Z-transformation of power spectral density
values (PSD) for the averages of the F4, O1 and O2 deri-
vations are given in table 3. Eight RRMS patients (out of
19) had PSD values for beta-2 and gamma of more than
two standard deviations compared to the mean of the
control. The same analysis for the BMS and the control
groups showed that neither of them reached this limit.
Correlation analysis
No correlations were detected between QEEG scores and
age, EDSS or cognitive performance indexed by reaction
times and percentage of correct responses.
Discussion
The present study attempted to replicate the effect of
validity described in previous studies that used the Posner
paradigm [34,35]. The valid condition, that in which the
subject's attention is focused on a region of the visual
space, results in a faster response (33 ms) compared to the
invalid condition, where the focus of attention has to be
reoriented toward another region of the visual field.
Regarding the global differences among the groups, reac-
tion time results indicate a poorer execution of the task in
RRMS and BMS patients than in controls. Indeed, the BMS
group exhibited fewer correct responses than the control
group. Both results indicate a certain cognitive deteriora-
tion of the MS groups, noticeably more marked in the
BMS group.
It is remarkable that the differences between the patholog-
ical and the control group are not caused by a speed- vs
accuracy  trade-off. In this sense, MS groups showed
impaired performance on both accounts, i.e. slower reac-
tion times in BMS and RRMS, and lower percentage of cor-
rect responses (for BMS patients only). This higher degree
of cognitive impairment in the BMS group than the RRMS
group has been previously observed [40].
The conclusion in our study is that the development of a
subclinical cognitive disability not detected by neurologi-
cal exploration could progress to greater cognitive deteri-
oration. Therefore, it should be possible to assess
cognitive status using behavioural techniques and cogni-
tive paradigms.
Regarding the quantitative analysis of the EEG (QEEG),
the main result is that, in general, RRMS patients exhibit a
larger amplitude for the high bands of the spectrum (beta-
2 and gamma) compared to the control and BMS groups
in specific regions of the scalp (occipital bilateral and right
frontal regions). The rest of the bands (delta, theta, alpha
and beta-1) showed no significant difference among the
various experimental groups.
This increment for the spectral high bands coincides with
other studies where similar increments have been related
to psychiatric diseases [25], or in this particular case, to
multiple sclerosis [27]. However, the absence of this incre-
ment in the background activity in our study suggests that
it is more sensitive to calculate spectral variations during
the execution of the cognitive task.
Using the same approach, but with the oddball paradigm
as the cognitive task, a similar increment in the high
bands was found [33]. In this case, a spectral modulation
was observed specifically in frontal regions, not in the
posterior areas of the scalp. Therefore, it seems that during
attentional tasks for diverse sensorial modalities (visual or
auditory), it is possible to find different spectral modula-
tions considering the topographical factor. However, a
remarkable difference exists between the two experiments
about the time at which the window of the PSD was cal-
culated.
In the auditory study, FFT analysis was done after the
arrival of the imperative stimulus, with the logical contri-
bution of the evoked potentials related to the stimulus,
and hence the possible influence of ERPs on the lower
limit of the beta-band values. In the present experiment,
calculation of the PSD was carried out prior to the arrival
of the imperative stimulus. In this interval, the average in
the time domain shows a well-known component called
"contingent negative variation" (CNV). The spectral pro-
file of this component is concentrated mainly in the delta
range (0.5. 4 Hz) and is unlikely to cause the modulations
observed in the beta and gamma ranges. This experiment
confirms that the increment observed for high bands of
EEG are not due to the contribution of ERPs and should
be considered as an abnormal correlate during attentional
process in MS patients.
Before we attempt to define the possible explanation for
this modulation, it is necessary to discard some alterna-
tives. One possible concern in our case is ocular contami-
nation. However, if ocular artefacts have an effect onBMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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Power Spectral Density (PSD) of different bands Figure 2
Power Spectral Density (PSD) of different bands. Different colours represent every spectral band (delta (0.5 – 4 Hz): 
blue colour; theta (5 – 8): green; alpha (9 – 12 Hz): red; beta (13 – 30 Hz): yellow and gamma (31 – 45 Hz): white. A) Subtrac-
tion of RRMS scores from control values. B) Subtraction of BMS scores from control values. CON: Control group; RRMS: 
relapsing-remitting group; BMS: Benign group.
A
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frontal electrodes, similar contribution would be expected
in both derivations (F3 and F4), which is contrary to what
is found (only F4 showed the statistical difference).
Further evidence is that the differences observed in occip-
ital regions must be considered genuine because these are
distant from the ocular source, and the intermediate
regions (central and parietal) do not exhibit any incre-
ment in the high bands.
The increment of high bands could also be caused in dif-
ferent ways by medication. For example, an increment in
the beta band has been detected after administration of
psychoactive drugs [25]. Other changes in the EEG could
be associated to immunomodulatory substances, such as
interferon-beta (IFN-beta), which has been referred by
other authors [29]. However, it should be remembered
that all the recruited patients were free of any kind of med-
ication during their participation in the experiment (at
least one month window).
Another possible interpretation for the increment in the
beta-2 and gamma bands could be from a higher level of
anxiety, a concerned raised by some authors [41].
Although, this phenomenon could appear in some sub-
jects during the recording, it is unlikely that only RRMS
patients experience this anxious. This argument could be
applied to other variables, such as a different level of
motivation or arousal.
Another concern is the possibility that harmonic compo-
nents (mainly alpha contribution) could be responsible
for differences in other spectral components (beta2 and
gamma), as suggested by other authors [42,43]. However,
differences were not statistically significant among the
various groups for the slowest bands in the spectral EEG
(delta, theta or alpha).
Finally, it is necessary to discard inference due to muscle
activity (we are grateful to one of the referees for this com-
ment). The same argument for the anxiety or motivational
level could be employed. Again, it is improbable that only
Table 2: Post Hoc results for spectral analysis of beta-2 and gamma bands
BETA-2
Descriptive F3 F4 O1 O2
L R LRLRLR
BMS 2.152 2.185 1.986 1.984 1.445 1.467 1.419 1.418
RRMS 2.487 2.456 2.457 2.450 1.944 1.941 1.873 1.898
CON 1.850 1.877 1.748 1.770 1.307 1.320 1.306 1.307
ANOVA F P
BxLxHxExG 1.941 0.009
Post Hoc CON CON CON CON
L R LRLRLR
RRMS 0.102 0.135 0.022 0.040 0.023 0.035 0.037 0.042
BMS 1.000 1.000 0.792 0.785 0.424 0.550 0.432 0.465
GAMMA
Descriptive F3 F4 O1 O2
L R LRLRLR
BMS 1.177 1.177 1.038 1.052 0.800 0.808 0.759 0.767
RRMS 1.325 1.290 1.300 1.289 1.094 1.085 1.059 1.040
CON 0.973 0.968 0.870 0.858 0.710 0.711 0.713 0.714
ANOVA F P
BxLxHxExG 1.941 0.009
Post Hoc CON CON CON CON
L R LRLRLR
RRMS 0.196 0.182 0.034 0.029 0.015 0.016 0.034 0.040
BMS 1.000 1.000 0.945 1.000 0.435 0.517 0.348 0.434
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign group. Side Stimulus Location: L (Left) and R (Right).BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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the RRMS patients showed this activity. Two additional
analyses (omitted for brevity) were conducted related to
this issue. In the first case, to discard the threat from mus-
cle artefact, we analysed the temporal electrodes (T5 and
T6) and no increase in beta and gamma bands was
detected on them. On the other hand, another analysis
was performed to check if the increase of the spectral
modulations was present all along the bands or specifi-
cally in the high bands (beta and gamma). A relative
power analysis of all the spectra indicated that only beta
and gamma bands showed an increase for multiple sclero-
sis patients and the relative power of slow bands was
higher in control subjects.
In the individual analysis of QEEG scores, a relevant find-
ing was the presence of abnormal high band activity in
RRMS patients and the absence from the BMS and the
control group. About 42% of RRMS patients showed
abnormal beta-2 activity (over 2 SD), and 37% of these
patients for the gamma band.
This result is truly outstanding; although the sensitivity of
the technique is modest for the detection of those subjects
with RRMS (42%), the probability that a control subject
or a BMS patient would be a false positive can be consid-
ered null, at least after this preliminary study and with a
discrete sample of patients.
Another relevant result that helps in interpreting the high
EEG modulations is the absence of any correlation
between QEEG scores and cognitive impairment assessed
on behavioural grounds. This result agrees with other
studies that failed to find a correlation between physiolog-
ical parameters and cognitive deterioration [30,44]. One
possible cause is that the physiological index (QEEG of
high bands) and the cognitive process are not related
directly. Indeed, the increment of the high bands of the
EEG has been associated with diverse psychiatric patholo-
gies [25] where the cognitive deteriorations can be
diverse.
If cognitive status is not related to these modulations,
what could be the reason for the modulation of high beta
bands of EEG in some RRMS subjects and not in the rest
of the groups?
One proposal comes from studies that have suggested
adaptive cortical functional changes in response to the
progression of the disease [45,46]. In these studies, an
increment in the activity of brain areas normally devoted
to the performance of a given task was found. But, there
was also an additional recruitment of areas not activated
in healthy people.
The lack of correlation between cognitive impairment and
the QEEG scores in the present experiment suggests that
Table 3: Clinical, behavioural and quantitative EEG data from 
subjects participating in the study
AGE DE EDSS RT BETA-2 GAMMA
RRMS 1 32 4 2 587* 1.11 0.59
RRMS 2 31 2 0 488 2.37* 1.35*
RRMS 3 41 4 1.5 560 1.03 0.52
RRMS 4 29 2 1 540 1.51 0.84
RRMS 5 31 3 1.5 436 2.61* 1.44*
RRMS 6 52 8 3 455 2.76* 1.56*
RRMS 7 53 18 2 473 1.69 0.84
RRMS 8 42 2 2 548 1.06 0.59
RRMS 9 38 3 2.5 480 2.98* 1.88*
RRMS 10 35 5 1.5 411 1.3 0.71
RRMS 11 46 6 3 493 1.76 1.01
RRMS 12 32 3 1.5 552 1.02 0.53
RRMS 13 34 1 0 470 1.68 0.93
RRMS 14 41 5 1.5 535 4.87* 2.87*
RRMS 15 29 5 1 536 2.23 1.14
RRMS 16 34 6 1.5 547 2.55* 0.97
RRMS 17 40 14 1.5 587 2.06 1.1
RRMS 18 38 7 1.5 642* 2.46* 1.2
RRMS 19 24 5 1.5 552 2.67* 1.59*
BMS 1 45 10 1 552 1.91 1.09
BMS 2 37 8 0 606* 1 0.45
BMS 3 46 16 3.5 630* 1.31 0.71
BMS 4 56 11 2.5 616* 1.96 1.16
BMS 5 41 12 2 606* 1.59 0.81
BMS 6 37 14 2.5 500 1.7 0.77
BMS 7 36 22 2.5 418 1.11 0.69
BMS 8 28 12 1 490 1.95 0.95
BMS 9 43 8 3.5 544 1.93 1.06
BMS 10 36 10 1.5 544 1.7 0.97
CON 1 32 . . 433 2.15 1.15
CON 2 31 . . 406 1.88 0.9
CON 3 23 . . 526 1.27 0.66
CON 4 35 . . 489 2.01 1.11
CON 5 31 . . 430 1.13 0.58
CON 6 54 . . 476 1.09 0.56
CON 7 38 . . 398 1.95 1.12
CON 8 33 . . 507 1.5 0.81
CON 9 35 . . 495 1.18 0.67
CON 10 51 . . 484 1.47 0.68
CON 11 26 . . 382 1.68 0.89
CON 12 36 . . 342 1.81 0.94
CON 13 42 . . 522 1.18 0.69
CON 14 35 . . 505 1 0.5
CON 15 42 . . 398 1.46 0.79
CON 16 36 . . 422 1.09 0.58
CON 17 36 . . 481 1.33 0.59
CON 18 35 . . 419 1.35 0.67
CON 19 41 . . 573 0.9 0.43
CON 20 34 . . 550 1.73 0.89
CON 21 21 . . 354 1.41 0.72
CON: Control group; RRMS: relapsing-remitting group; BMS: Benign 
group. DE: Disease evolution (years); EDSS: Expanded Disability 
Status Scale. RT: Reaction Time (ms); BETA-2 and GAMMA (Power 
Spectral Density (μV2). PSD values presented in the table were 
obtained as an average of the three statistical significant scalp 
positions (F4, O1 and O2). Values with an asterisk (*) are over +2 
Standard Deviation.BMC Neurology 2008, 8:44 http://www.biomedcentral.com/1471-2377/8/44
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the increment of activation (beta2- and gamma) in the
cortex could not always be related to the performance of
the cognitive task. Indeed, the BMS group showed a
higher degree of cognitive impairment and the QEEG
scores remained in the normal range. It is possible that
there are several mechanisms activated during the MS
course. One possibility that has been pointed out [23]
could be an adaptive response in the brain to compensate
for cognitive impairment, and on the other hand, a non-
specific response in the brain (reflected by the increase of
high bands of EEG) activating general compensatory
mechanisms in response of the progression of the disease,
but not strictly related to the cognitive impairment.
Studies have supported that notion that in the first phases
of the disease, some processes of cortical reorganization
appear [47] with redistribution of ionic channels [48] as
lesions arise in certain tissues. These adaptive processes
are thought to occur in the early lesions and remain sub-
clinical [49]. Our interpretation of the increment of the
high bands of the EEG is that they are electrophysiological
correlates of some of these processes occurring specifically
in some of the RRMS patients.
But why do these modulations not happen with the rest of
the patients with RRMS and in all BMS patients? First, this
might be explained by some RRMS patients still being in
early phases of the disease, and have not begun the reor-
ganizational processes. Another possibility is that some of
these have patients in fact are already drained of some
form of "natural reserve", and therefore begin to develop
a permanent disability [50] and no high band increment
can be observed.
In the case of the BMS patients, perhaps a slow evolution
of the disease is not activating the mechanisms of cortical
reorganization and in consequence no modulations of
EEG are shown. Some form of this "natural reserve"
would be activated to compensate for cognitive impair-
ment [23] but some more general cortical plasticity could
not be started (failing to show the increase of high bands
of the EEG).
Some challenges are opened after these results. First of all,
it seems desirable to increase the sample in order to check
if these results are consistently enough for MS population.
Another important issue in the future would be to corre-
late these QEEG scores with MRI features (we are grateful
to one of the referees about this comment). In the same
sense, it would be interesting to check, from the early
beginning of the disease, possible "high band profile" to
understand the exact meaning of this correlate and the
activation of plastic mechanisms. Particularly interesting
would be a follow-up study with RRMS patients and the
modulations in the high bands related to relapses or the
conversion to the SPMS (secondary progressive multiple
sclerosis) form.
This interpretation of the results, also suggests the possi-
bility that the increment of high bands of the EEG is not
in fact a specific marker for any pathology, but rather an
indicator of a natural reaction in the brain before the
appearance of lesions or dysfunctions that can be present
in diverse pathologies. Regrettably, it is not possible to
confirm this hypothesis definitively by the light of our
results. More studies would be necessary to confirm this
new point of view in the way that we interpret beta and
gamma EEG modulations.
Conclusion
An increment of the high bands of the spectrum appears
in the patients with MS although the localization of this
modulation was observed in a different topography com-
pared to other similar experiments probably caused by the
use of a different sensorial modality. Also, the study has
shown that QEEG scores do not correlate with the cogni-
tive impairment, which indicates a relative independence
of both variables as has been described in other studies.
Probably, the most relevant result in the present study is
that BMS and RRMS patients exhibited different physio-
logical patterns as could be observed with QEEG scores.
The possible interpretation of this fact is speculative, but
it points out that the increment of the high bands of the
EEG could represent the activation of cortical reorganiza-
tion processes activated in RRMS patients. In the case of
BMS patients, these processes would not be activated
which could explain why these patients suffer a slow
advance and subclinical manifestation of the disease dur-
ing years of evolution.
The lack of correlation between QEEG scores and cogni-
tive impairment does not mean a complete independence
between these two processes. An increment in the high
band QEEG scores could be an alerting signal to activate
compensatory mechanisms that of course will help in the
cognitive performance of the subject.
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